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Conversion disorder (CD) now recognised as functional neurological symptom disorder 
(DSM V) presents with physical symptoms that are not well explained by organic aetiology. 
We describe a unique case of Conversion Parkinson’s Disease (PD).  
Ms D is a 34-year-old single woman. The salient points in her background included physical 
and emotional abuse by her father. She was an anxious child with tendency to somatise 
distress. She developed chronic unexplained fatigue with muscle aches that led to a diagnosis 
of fibromyalgia by a rheumatologist when she was 24. There is also a family history of 
bipolar disorder in her mother and schizophrenia in in second and third degree relatives. Her 
personality style was characterised by borderline and dependant traits, with a history of 
affective dysregulation and defence mechanisms of idealization and devaluation, splitting and 
projection evident during her hospitalisation.  
She met her recently deceased partner, who was 30 years older when she was 27. He was the 
leader of a religious cult group whom she strongly idealised as a paternalistic figure. Her 
partner was diagnosed with PD and treated with L-dopa. In the context of being with a 
charismatic and persuasive individual, Ms D started developing somatic symptoms including 
tremors, unsteady gait, varying degrees of paralysis and neuropathic pain, which he attributed 
to PD and encouraged her to use his L-dopa. She had no prior history of levodopa-induced 
euphoria or psychosis. With self-reporting of unconfirmed PD, Ms D procured constant 
supply of L-dopa through various GPs. She was taking Levodopa-Benserazide 
(Madopar)200mg-50mg capsules every 6 hours and 4mg transdermal Rotigotine patches.  
She gradually increased the dose over five years and rationalised the dose increases as 
preventing withdrawal symptoms like spasms, agitation and fatigue. 
She presented to local Emergency Department following an acute conscious collapse. No 
medical cause could be identified for her collapse. Persecutory delusions and auditory 
hallucinations were noted during her medical admission, requiring transfer to a psychiatric 
ward. She was diagnosed with L-dopa induced psychosis. Her atypical presentation of PD 
was formulated to be a conversion disorder with predominantly unconscious motivation and 
symptom production, on the background of emotional vulnerability secondary to her early 
trauma history, past history of somatisation and borderline/dependant traits. Her unique 
parkinsonian presentation was speculated to be influenced by the symptomatic template of 
her partner with PD, whom she idealised as a father figure. 
Following review by a neurologist, PD was excluded and Dopamine Replacement Therapy 
(DRT) was ceased, which caused distress. Subsequent psychiatric review offered her an 
alternative explanation of her symptoms, which she found acceptable. Ms D was prescribed 
Aripiprazole, and psychosis resolved within a week. Following cessation of L-dopa, her non-
apparent parkinsonian features further substantiated our formulation of conversion PD.  
This is the first reported case of Conversion PD with a previous report where the patient 
embellished her existing PD symptoms in order to obtain a higher dose of L-dopa and gain 
was to obtain the sick role1. It is interesting that despite the higher prevalence of PD in 
comparison to epilepsy2,3, the former provides a more common symptomatic template for 
abnormal illness behaviour.  
L-dopa has intrinsic reinforcement properties and is closely linked to the reward pathways of
the brain4. It is a drug that stimulates both direct and indirect pathways in the striatum,
therefore has high dependence potential. Its abuse in PD patients is a well-recognized
phenomenon and has been referred to as hedonistic homeostatic dysregulation5 and dopamine
dysregulation syndrome by various authors to avoid the stigmatizing label of addiction6. Its
prevalence in PD is thought to be around 4%7 in tertiary care setting. It has been discussed
and debated whether it can actually be a drug of abuse given its dependence is largely
iatrogenic rather than recreational8. There have only been a few reports of L-Dopa abuse in 
non-PD setting which is rather surprising, given its potential addictive properties9, and might 
indicate the complexities that underlie that neurobiology of addiction.  
 
L-Dopa induced psychosis in the setting of PD is common with an incidence of 22%10. It is 
because while trying to stabilize the nigrostriatal dopaminergic system, levodopa destabilizes 
the mesolimbic system. It usually resolves following cessation of the drug but sometimes 
requires the addition of an antipsychotic medication if L-Dopa is unable to be ceased. 
 
Whilst the addiction construct and L-dopa abuse is an area of controversy in PD, clinical 
suspicion should be raised in young onset PD with atypical features. Specialist neurologist 
advice should be sought before consideration of L-dopa therapy and screening for 
psychological factors be done in such cases. Despite the reinforcing effect of L-dopa, it is 
surprising that there have not been many cases of recreational abuse of this drug, and it does 
not form part of the restricted formulary.  The authors believe that it is under-reported, which 
is worthy of further clinical and biological research. 
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